Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2203 in Refractory Autoimmune Diseases
NCT06747156Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, RNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABO2203 in autoimmune diseases, sponsored by Ruijin Hospital. Primary endpoints: Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
ABO2203
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT06747156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747156.